ESPR · As filed with the SEC

Esperion Therapeutics income statement, by quarter

The statement as Esperion Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Condensed Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts

USD thousands, except per-share amounts	Q1 2026 3 months ended Mar 31, 2026	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025 3 months ended Sep 30, 2025	Q2 2025 3 months ended Jun 30, 2025
Revenues:
Total Revenues	80,104	168,446^†	87,309	82,385
Product sales, net	43,391	43,723^†	40,659	40,274
Collaboration revenue	36,713	124,723^†	46,650	42,111
Operating expenses:
Cost of goods sold	34,573	—	41,289	28,543
Research and development	8,988	13,926^†	14,131	7,238
Selling, general and administrative	43,124	41,433^†	41,848	39,509
Total operating expenses	86,685	83,213^†	97,268	75,290
Loss from operations	(6,581)	85,233^†	(9,959)	7,095
Interest expense	(19,798)	(22,636)^†	(22,051)	(20,486)
Loss on extinguishment of debt and exchange transaction	—	0^†	0	0
Other income, net	1,183	1,075^†	677	666
Net loss	(25,196)	61,831^†	(31,333)	(12,725)
Net loss per common share - basic (in dollars per share)	(0.10)	—	(0.16)	(0.06)
Net loss per common share - diluted (in dollars per share)	(0.10)	—	(0.16)	(0.06)
Weighted-average shares outstanding - basic (in shares)	251,353,086	—	200,736,136	197,546,239
Weighted-average shares outstanding - diluted (in shares)	251,353,086	—	200,736,136	197,546,239
Comprehensive loss	(25,196)	61,831^†	(31,333)	(12,725)

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.